Naples Money Management LLC Purchases Shares of 441 Eli Lilly and Company (NYSE:LLY)

Naples Money Management LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 441 shares of the company’s stock, valued at approximately $257,000.

Several other institutional investors have also recently made changes to their positions in the company. Zhang Financial LLC increased its stake in Eli Lilly and Company by 2.1% in the 4th quarter. Zhang Financial LLC now owns 1,672 shares of the company’s stock worth $975,000 after acquiring an additional 34 shares during the last quarter. Beaumont Financial Advisors LLC increased its position in shares of Eli Lilly and Company by 2.1% in the fourth quarter. Beaumont Financial Advisors LLC now owns 6,356 shares of the company’s stock worth $3,705,000 after purchasing an additional 129 shares during the last quarter. Andrew Hill Investment Advisors Inc. purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $1,105,000. HTLF Bank purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $444,000. Finally, Kellett Wealth Advisors LLC lifted its position in Eli Lilly and Company by 5.4% during the fourth quarter. Kellett Wealth Advisors LLC now owns 1,371 shares of the company’s stock valued at $799,000 after purchasing an additional 70 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Bank of America boosted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Citigroup increased their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Trading Down 2.6 %

Shares of LLY traded down $19.64 during trading hours on Friday, reaching $726.31. 3,486,055 shares of the company traded hands, compared to its average volume of 3,073,465. Eli Lilly and Company has a 12 month low of $369.76 and a 12 month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company’s fifty day moving average price is $764.24 and its two-hundred day moving average price is $658.28. The company has a market capitalization of $690.11 billion, a price-to-earnings ratio of 125.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the business posted $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.